Chugai Pharma USA
Business Services · New Jersey, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
300 Connell Dr Ste 3100, Berkeley Height...Phone Number
(908) 516-1350Website
www.chugai-pharm.comRevenue
$22 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Chugai Pharma USA
Chugai Pharma USA, Inc. (CPUSA) is a subsidiary of Chugai Pharmaceutical Co., Ltd., located in Berkeley Heights, NJ. The company specializes in planning and executing global and U.S. clinical programs for innovative new drug candidates developed by Chugai. CPUSA emphasizes partnerships in healthcare solutions and is committed to integrity and social responsibility in its operations. They also offer career opportunities for individuals looking to join their mission to improve patient outcomes.Explore more
Chugai Pharma USA Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Chugai Pharma USA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Chugai Pharma USA has new funding data
Earning: See what the market has to say on Chugai Pharma USA recently announced quarterly report
Chugai Pharma USA, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Chugai Pharma USA is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Chugai Pharma USA has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Chugai Pharma USA launches new products
Congratulate Masked Content for being promoted to Masked Content at Chugai Pharma USA
Click to see if Chugai Pharma USA had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Chugai Pharma USA
Compare insights from companies similar to Chugai Pharma USA, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Chugai Pharma USA
$22M
201-500
Private
-
1995
YI
Yoshio ItayaBoard Member, Executive Vice President, Chief Financial Officer, General Manager of Finance Supervisory Division, General Manager of Finance and Accounting Department and General Manager of Information Technology Supervisory Division
Company Profile Activity
Activity Insights
Chugai Pharma USA is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Chugai Pharma USA is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Chugai Pharma USA.
Chugai Pharma USA Tech Stack
A closer look at the technologies used by Chugai Pharma USA
Most Recent Scoops
Event
Events
Promotion
Executive Move
Tatsuro Kosaka has recently been promoted from Chief Operating Officer to President & Chief Executive Officer.
Executive Moves, Promotion, Personnel Moves
Lateral Move
Executive Move
Osamu Nagayama, who previously served as Chief Executive Officer, has been named Chairman & Representative Director.
Executive Moves, Lateral Move, Personnel Moves
Project
Cloud, Implementation, Analytics & Insights, Clinical Systems, Data Management
Chugai Pharma USA News & Media
Chugai's HEMLIBRA® Receives Regulatory Approval from U.S. FDA for Hemophilia A Without Inhibitors
TOKYO--(BUSINESS WIRE)--#biotech--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA® (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks. The FDAResults of Global Phase III Study with Chugai's HEMLIBRA® for Hemophilia A Without Inhibitors Published in the New England Journal of Medicine
TOKYO--(BUSINESS WIRE)--#biotech--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) today announced that results of the HAVEN 3 study (NCT02847637), the global phase III study evaluating hemophilia A treatment, HEMLIBRA® (generic name: emicizumab [genetical recombination]), were published in the 30 August 2018 issue of the New England Journal of Medicine (NEJM).Article: https://www.nejm.org/doi/full/10.1056/NEJMoa1803550Quick video summary by NEJM: https://www.nejm.org/do/10.1056/NEJMdo005333/full/ TChugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab," Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online
TOKYO--(BUSINESS WIRE)--#atopicdermatitis--Long term data from global phase 2 study for Chugai's nemolizumab was published in Journal of Allergy and Clinical Immunology Online.Chugai's HEMLIBRA® Receives Breakthrough Therapy Designation from U.S. FDA for Hemophilia A Without Factor VIII Inhibitors
TOKYO--(BUSINESS WIRE)--#biotech--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its anti-coagulation factor IXa/X humanized bispecific monoclonal antibody / coagulation factor VIII substitute, “HEMLIBRA®” [US generic name: emicizumab-kxwh] for people with hemophilia A without factor VIII inhibitors. Development and distribution of the drug in the US is conducted by Genentech, a member
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Chugai Pharma USA
Sign Up For FreeTo access detailed company insights
Chugai Pharma USA, Inc. (CPUSA) is a subsidiary of Chugai Pharmaceutical Co., Ltd., located in Berkeley Heights, NJ. The company specializes in planning and executing global and U.S. clinical programs for innovative new drug candidates developed by Chugai. CPUSA emphasizes partnerships in healthcare solutions and is committed to integrity and socia... Read More
